<it>Ex vivo </it>activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of <it>Plasmodium falciparum</it>
<p>Abstract</p> <p>Background</p> <p>The aim of the present work was to assess i) <it>ex vivo </it>activity of pyronaridine (PND) and piperaquine (PPQ), as new components of artemisinin-based combination therapy (ACT), to define susceptibility baseline, ii)...
Main Authors: | Pascual Aurélie, Parola Philippe, Benoit-Vical Françoise, Simon Fabrice, Malvy Denis, Picot Stéphane, Delaunay Pascal, Basset Didier, Maubon Danièle, Faugère Bernard, Ménard Guillaume, Bourgeois Nathalie, Oeuvray Claude, Didillon Eric, Rogier Christophe, Pradines Bruno |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-02-01
|
Series: | Malaria Journal |
Subjects: | |
Online Access: | http://www.malariajournal.com/content/11/1/45 |
Similar Items
-
Review of pyronaridine anti-malarial properties and product characteristics
by: Croft Simon L, et al.
Published: (2012-08-01) -
Population pharmacokinetics and pharmacodynamics of pyronaridine
by: Methaneethorn, Janthima
Published: (2013) -
Population pharmacokinetics of pyronaridine in the treatment of malaria
by: Wattanavijitkul, Thitima
Published: (2010) -
Plasmodium falciparum gametocyte dynamics after pyronaridine–artesunate or artemether–lumefantrine treatment
by: Johanna M. Roth, et al.
Published: (2018-06-01) -
Global gene expression profiling of <it>Plasmodium falciparum </it>in response to the anti-malarial drug pyronaridine
by: Chavalitshewinkoon-Petmitr Porntip, et al.
Published: (2011-08-01)